EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone

Matthew N Mills, Akihiro Uno, Pinxue Li, Casey Liveringhouse, Youngchul Kim, Daniel E Oliver, Bradford A Perez, Benjamin C Creelan, Michael Yu, Peter A Forsyth, Yolanda Pina, Kamran A Ahmed

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Matthew N Mills und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: EGFR-targeted therapy (ETT) and immune-checkpoint blockade (ICB) have shown promising results in treating NSCLC brain metastases (BM). However, little is known of their effect in treating leptomeningeal disease (LMD). PATIENTS AND METHODS: This is a retrospective review of 80 patients diagnosed with NSCLC LMD from January 2014 to March 2021. Patients were grouped based on initial LMD treatment: radiotherapy (RT) alone, ETT, ICB, and intrathecal chemotherapy (ITC). RESULTS: EGFR mutation was present in 22 patients (28%). Twenty patients had positive cytology in cerebrospinal fluid, while 60 patients were diagnosed based on MRI with clinical correlation. The RT alone group consisted primarily of whole brain radiation (n = 20; 77%), stereotactic radiation (n = 3; 12%), and palliative spine radiation (n = 2; 7%). There were no significant differences amongst the treatment groups in age, performance status, or neurologic symptoms. Overall, the 6-month overall survival (OS) and craniospinal progression free survival (CS-PFS) were 35% and 24%, respectively. The 6-month OS for the ETT, ICB, ITC, and RT alone groups was 64%, 33%, 57%, and 29% respectively (log-rank P = .026). The 6-month CS-PFS for the ETT, ICB, ITC, and RT alone groups was 43%, 33%, 29%, and 19% respectively (log-rank P = .049). Upon univariate analysis, receipt of ETT compared to RT alone reached significance for OS (HR 0.35, P = .006) and CS-PFS (HR 0.39, P = .013). CONCLUSIONS: The prognosis for patients with NSCLC LMD remains poor overall. However, the receipt of ETT for patients with EGFR-positive disease was associated with improved outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedInjections, SpinalMeningeal NeoplasmsAdultMeningeal CarcinomatosisMolecular Targeted TherapyAged, 80 and overSurvival RateAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyPrognosisTreatment OutcomeFollow-Up StudiesMutation

Stichwörter der Autor:innen

EGFR-targeted therapyImmune checkpoint blockadeLeptomeningeal diseaseNon-small cell lung cancerRadiation therapy

Substanzen

ErbB ReceptorsEGFR protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Morsani College of Medicine, University of South Florida, Tampa, FL.
  • Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
  • Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Electronic address: yolanda.pina@moffitt.org.

Zitieren

APA

Mills, M. N., Uno, A., Li, P., Liveringhouse, C., Kim, Y., Oliver, D. E., Perez, B. A., Creelan, B. C., Yu, M., Forsyth, P. A., Pina, Y., & Ahmed, K. A. (2024). Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.04.005

Vancouver

Mills MN, Uno A, Li P, Liveringhouse C, Kim Y, Oliver DE, et al. Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.04.005

BibTeX
@article{Mills2024,
  author = {Mills, Matthew N and Uno, Akihiro and Li, Pinxue and Liveringhouse, Casey and Kim, Youngchul and Oliver, Daniel E and Perez, Bradford A and Creelan, Benjamin C and Yu, Michael and Forsyth, Peter A and Pina, Yolanda and Ahmed, Kamran A},
  title = {Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.04.005}
}
Kostenlos starten →